CompletedPhase 1NCT02365532
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Studying Congenital long QT syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Kimberly B Patel, MDGilead Sciences
- Intervention
- GS-6615(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18-40 years · All sexes
- Timeline
- 2015 – 2015
Study locations (1)
- Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02365532 on ClinicalTrials.govOther trials for Congenital long QT syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06887387Wearable Devices for Patient Monitoring in Long QT SyndromeQueen Mary University of London
- ENROLLING BY INVITATIONNANCT07233421Frequency of Hypoglycemia in Children With Beta-blocker Treated Long QT-syndromeHelsinki University Central Hospital
- RECRUITINGNANCT04336644Continuous Versus Intermittent cARdiac Electrical moNitorinGWashington University School of Medicine
- RECRUITINGNANCT05348564Comparing Direct vs Indirect Methods for Cascade ScreeningUniversity of Maryland, Baltimore
- RECRUITINGNCT06087367Building of a Diagnostic/Prognostic Database for Human ERG Variant EffectsNantes University Hospital